949969-59-9Relevant articles and documents
CNS-ACCESSIBLE PHARMACOLOGICAL CHAPERONES FOR TREATMENT OF ACID BETA-GLUCOSIDASE-RELATED DISEASE STATES
-
Paragraph 0013; 0128, (2019/02/01)
Disclosed herein are β-glucosidase (GCase) chaperones and methods of using GCase chaperones in an individual in need thereof. GBA1 mutations lead to GCase deficiency and substrate accumulation, causing Gaucher disease. Currently, no FDA or EMA-approved th
SALICYLIC ACID DERIVATIVES USEFUL AS GLUCOCEREBROSIDASE ACTIVATORS
-
Paragraph 0090, (2013/10/21)
Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of G